Open AccessAdoptive transfer of tumor specific T cells from allogeneic donors is feasible, effective and safe alternative to autologous T cell based tumor immunotherapy
Author(s) -
Eliza Kwiatkowska-Borowczyk,
Anna Kozłowska,
Klaudia Maruszak,
Luiza KańczugaKoda,
Mariusz Koda,
Monika Dajnowiec,
Andrzej Maćkiewicz,
Dariusz W. Kowalczyk
Publication year - 2014
Publication title -
journal of medical science
Language(s) - English
Resource type - Journals
eISSN - 2353-9801
pISSN - 2353-9798
DOI - 10.20883/medical.e39
Subject(s) - adoptive cell transfer , immunotherapy , immunology , medicine , graft versus host disease , t cell , cyclophosphamide , cancer research , cell therapy , transplantation , immune system , biology , cell , chemotherapy , genetics
Donor lymphocyte infusion is used to increase the graft versus tumor (GVT) effect after allogeneic hematopoietic cell transplant. The limited spectrum of activity and high risk of graft versus host disease (GVHD) remain major limitations of this approach. The finding of new cell populations for adoptive immunotherapy, with the ability to separate GVT from GVHD, would be useful. In the present manuscript, we tested in mouse model the use of allogeneic MHC partially matched effector cells for adoptive T cell immunotherapy of cancer. We sought to maximize graft-versus-tumor effect while minimizing GVHD using tumor-specific allogeneic effector T cells rather than open-repertoire T cells. A F1 hybrid (Balb/c x C57BL/6) -MethA-EGFP–bearing mice received a preparative regimen of nonmyeloablating cyclophosphamide lymphodepletion followed by adoptive transfer of bulk Balb/c derived allogeneic T cells specific for the MethA-EGFP tumor cells. Adoptively transferred allogeneic tumor-specific T lymphocytes prevented tumor formation without graft versus host disease – like symptoms. We found that the risk of GVHD was low even with high number of transferred tumor-specific T cells. These data indicate that the use of tumor-specific allogeneic T cells is feasible, effective and safe alternative to autologous T cell based tumor immunotherapy.